Anavex Life Sciences Corp. (AVXL)
| Previous close | 17.38 |
| Open | 17.45 |
| Bid | 17.92 x 1200 |
| Ask | 17.95 x 1800 |
| Day's range | 17.23 - 18.00 |
| 52-week range | 4.51 - 31.50 |
| Volume | 274,385 |
| Avg. volume | 956,509 |
| Market cap | 1.255B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.45 |
| Earnings date | 04 Aug 2021 - 09 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.95 |
- Motley Fool
2 Biotech Stocks Set to Go Supernova Soon
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.
- GlobeNewswire
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at
- GlobeNewswire
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
The Company anticipates topline data in the second half of 2022NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the Independent Data Safety Moni
